Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of KC1036 in advanced recurrent or metastatic gastrointestinal tumors
CTR20220211Phase 2Active
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of connitinib in gastrointestinal cancer, Esophageal Squamous Cell Carcinoma (ESCC), Nonhematologic neoplasms, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Jun 2022; status: active.
02
Drugs
connitinib
03
Conditions
gastrointestinal cancerEsophageal Squamous Cell Carcinoma (ESCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220211.